NF2 Gene Mutation clinical trials at University of California Health
1 research study open to eligible people
Showing trials for
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
open to eligible people ages 18 years and up
This phase II trial studies how well vismodegib, focal adhesion kinase (FAK) inhibitor GSK2256098, and capivasertib work in treating patients with meningioma that is growing, spreading, or getting worse (progressive). Vismodegib, FAK inhibitor GSK2256098, capivasertib, and abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
at UC Davis UC Irvine UCSD UCSF
Our lead scientists for NF2 Gene Mutation research studies include Daniela A. Bota Orwa Aboud.
Last updated: